Clinical Trial Update: Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial is assessing safety, tolerability, and exploratory efficacy of AGP100 in patients with Catecholaminergic Polymorphic Ventricular Tac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Catecholaminergic Polymorphic Ventricular Tachycardia

Drugs mentioned

• AGP100

Snippet

Sponsor: Agiana Pharmaceuticals | Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia | Phase 2 | Status: RECRUITING